BioNTech SE logo

BNTX - BioNTech SE News Story

$194.5 -3.8  -1.9%

Last Trade - 18/05/21

Sector
Healthcare
Size
Large Cap
Market Cap £33.89bn
Enterprise Value £33.68bn
Revenue £2.15bn
Position in Universe 264th / 6846

Europe administers 17 mln COVID vaccine doses in latest week - ECDC

Thu 22nd April, 2021 11:13am
BERLIN, April 22 (Reuters) - Europe took delivery of, and administered, nearly 17 million doses of COVID-19 vaccines last week, according to a regular monitoring report that showed that a total of 116 million shots had been given as the region's campaign picks up. A total of 134 million doses have been sent to countries in the European Union and European Economic Area, working out at 35.9 doses per 100 inhabitants, the European Centre for Disease Prevention and Control (ECDC) said. The figures were contained in the ECDC's weekly report https://covid19-vaccine-report.ecdc.europa.eu, which was published on Thursday and covered the week ending last Sunday. Its separate Vaccine Tracker https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#distribution-tab, an online dashboard that is updated more often, showed on Thursday that 135 million doses had been sent to the EU and EEA in total, of which 117 million had been administered. On average, 23.3% of adults in the EU and EEA have received a first shot by last Sunday while 8.4% have been fully vaccinated, typically by getting a second injection. By contrast, 62% of Israelis have received at least one dose of COVID-19 vaccine, 49% in Britain and 40% in the United States, according to Our World In Data https://ourworldindata.org/covid-vaccinations. <^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ Latest coronavirus statistics, charts and maps https://graphics.reuters.com/world-coronavirus-tracker-and-maps/ ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^> (Reporting by Douglas Busvine Editing by Gareth Jones) ((douglas.busvine@tr.com; +49 30 220 133 562;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.